Related by context. All words. (Click for frequent words.) 71 CDAI score 69 SELENA SLEDAI score 66 alanine aminotransferase 66 Index CDAI score 66 MADRS score 66 Crohn Disease Activity 65 liver histology 65 Ishak fibrosis score 65 alanine aminotransferase ALT 65 lamivudine refractory patients 64 Scale cognitive subscale 63 ADAS cog 62 Expanded Disability Status 62 mEq L 61 #.#/#.# mmHg [001] 61 serum urate 61 SGPT 61 significant BILAG worsening 61 HBeAg seroconversion 60 HDRS 60 symptom severity 60 serum urate levels 60 CDAI 60 atheroma volume 60 glycated hemoglobin levels 60 adjunctive placebo 60 IRLS score 60 PANSS total 60 Scale EDSS 60 DAS# [002] 59 HbA 1c levels 59 -#.# mg dL [002] 59 sUA 59 Montgomery Asberg Depression 59 serum potassium 59 Hb A1C 59 aspartate aminotransferase 59 elevated ALT 59 % Confidence Interval 58 ADAS Cog 58 serum creatinine levels 58 EDSS score 58 mg TID 58 PSADT 58 HOMA IR 58 BPH Symptom Score 58 Alzheimer Disease Assessment 58 serum sodium 58 virologic response 58 Index CDAI 58 EDSS scores 58 proteinuria 58 mmol l 58 lumbar spine BMD 58 lopinavir r arm 58 IPSS 58 HbA1c levels 58 log# copies mL 58 ACR# response 58 YMRS 58 retinal thickness 58 CR nPR 57 leukopenia 57 ADCS CGIC 57 Severity MSCS score 57 NIH CPSI 57 IBDQ 57 x ULN 57 Scale EDSS score 57 TNSS 57 plus methotrexate 57 Psoriasis Area 57 HBeAg 57 weekly CSBMs 57 AUA BPH Symptom Score 57 hemoglobin A1c levels 57 salivary flow 57 mcg mL 57 serum testosterone 57 Negative Syndrome 57 mL/min/#.# m 2 57 serum HBV DNA 57 serum phosphorus 57 hypophosphatemia 57 Y BOCS 57 glomerular filtration rate 57 inflammatory lesions 57 hip BMD 57 aminotransferase levels 57 plasma HCV RNA 57 serum phosphate 57 creatinine clearance 57 elevated serum creatinine 57 micrograms mL 57 A1C levels 57 baseline HbA1c 57 X ULN 57 HbA1C levels 57 annualized relapse 57 serum ALT 56 macroalbuminuria 56 mIU L 56 creatinine ratio 56 hours postdose 56 CIN3 56 eosinophil count 56 CI -#.# 56 #.#/#.# mm Hg [003] 56 ACR Pedi 56 luminal diameter 56 pulmonary capillary wedge 56 placebo p 56 MCyR 56 serum PSA 56 4mg/kg 56 ADHD RS 56 Brief Psychiatric 56 Rating Scale MADRS 56 mmHg diastolic 56 % CI #.#-#.# [004] 56 serum BDNF 56 PASI scores 56 tirofiban 56 binary restenosis 56 SGOT 56 platelet reactivity 56 overt nephropathy 56 p = .# [002] 56 TAXUS p value 56 MMSE scores 56 Montgomery Åsberg Depression 56 neutrophil counts 56 serologically active patients 56 mg BID 56 recurrent venous thromboembolism 56 achieved statistical significance 56 moderate renal impairment 56 log# reduction 56 ACR# responses 56 CCyR 56 nephrotoxicity 56 HBV DNA levels 56 placebo p = 55 HAM D# scores 55 albumin excretion rate 55 8mg/kg 55 certolizumab 55 achieved ACR# 55 anemia hemoglobin 55 morphometric vertebral fractures 55 fasting plasma glucose FPG 55 neurodevelopmental impairment 55 oxycodone CR 55 mg BID dose 55 -#.# mg dL [001] 55 tolvaptan 55 hypoperfusion 55 Endothelial function 55 BPRS PSS 55 autoantibody levels 55 nasal symptom 55 PREZISTA r arm 55 hemoglobin A1c HbA1c 55 pCR 55 hyperphenylalaninemia HPA due 55 sustained virological response 55 #.#mg/dL 55 aminotransferases 55 NIHSS 55 ALT elevation 55 mRS 55 A1c levels 55 HbA 1c 55 extrapyramidal symptoms 55 NIHSS score 55 HAQ DI 55 left ventricular systolic 55 ALT elevations 55 infarct size 55 serum calcium levels 55 serum calcium 55 UPDRS motor 55 LVEF 55 lumbar spine bone 55 HER2 expression 55 ertapenem 55 PANSS 55 Score DAS# 55 complete cytogenetic response 55 urinary albumin 55 p = #.# [003] 55 glycated hemoglobin 55 apolipoprotein B 55 albumin excretion 55 myocardial reperfusion 55 blood glucose concentrations 55 AUA Symptom Score 55 ACTEMRA TM 55 hepatitis C genotype 55 achieved PASI 55 mL sec 55 titrated glipizide 55 urinary N telopeptide 55 mg/m2 dose 55 arterial thromboembolic events 55 fraction LVEF 55 baseline A1C 55 erythrocyte sedimentation rate 55 platelet inhibition 55 Pred Forte 55 SCr 54 serum clusterin levels 54 severe renal impairment 54 reinfarction 54 serum uric acid 54 leukocyte count 54 MMSE score 54 symptomatic VTE 54 abacavir lamivudine 54 hypomagnesemia 54 tolterodine ER 54 intima media thickness 54 PANSS scores 54 receiving VICTRELIS 54 p = .# [001] 54 corticosteroid dose 54 mg QD 54 receiving golimumab 54 adjunctive ABILIFY 54 antibody titer 54 REMICADE monotherapy 54 REYATAZ r arm 54 recurrent VTE 54 fasting plasma glucose 54 -#.# log# 54 TEAEs 54 intravascular hemolysis 54 transaminase elevations 54 plasma leptin 54 Rating Scale BPRS 54 mcg QD 54 dizziness nausea diarrhea 54 mmHg systolic 54 serum aminotransferase levels 54 peginterferon alfa 2a 54 ARB telmisartan 54 serum phosphate levels 54 permanently discontinue Vectibix 54 urinary oxalate 54 % CI #.#-#.# [007] 54 μg mL 54 serum transaminases 54 HbA1C 54 clodronate 54 glycosylated hemoglobin HbA1c 54 febrile neutropenia 54 mm Hg systolic 54 splenectomized 54 interleukin IL -6 54 cholesterol LDL C 54 intraocular pressure IOP 54 hematologic toxicity 54 target vessel revascularization 54 mTSS 54 apnea hypopnea index 54 urge urinary incontinence 54 arterial thickening 54 virologic 54 lymphocytosis 54 baseline serum creatinine 54 aspartate aminotransferase AST 54 lamivudine monotherapy 54 nonfatal MI 54 serum homocysteine 54 albuminuria 54 bone marrow reticulin 54 CrCl 54 gastric pH 54 KRAS mutant tumors 54 WOMAC pain 54 rectal bleeding subscore 54 P = .# 54 Viral load 54 mood lability 54 sUA levels 54 tapentadol ER 54 definite stent thrombosis 54 Intermediate maturities 54 statistically significant p = 54 plasma urate 54 PSA nadir 54 International Prostate Symptom 53 abdominal pain abdominal discomfort 53 UACR 53 neutrophil count 53 QTcF 53 leucopenia 53 HAMD 53 log# 53 pyrexia mucositis sepsis febrile 53 micromolar 53 Score IPSS 53 plasma triglycerides 53 DAS# CRP 53 carotid IMT 53 ACR# ACR# 53 UPDRS 53 μg dL 53 CK MB 53 Ocular Surface Disease 53 Pain Intensity 53 prespecified secondary 53 protein excretion 53 UPDRS scores 53 laboratory abnormalities 53 cells uL 53 mcg BID 53 HCV RNA 53 glomerular filtration 53 Sustained virologic response 53 SUVmax 53 hypokalemia 53 uncoated stent 53 microvessel density 53 hepatic fibrosis 53 ADCS ADL 53 antibody titers 53 μmol L 53 serum estradiol 53 ng dL 53 biochemical relapse 53 nmol L. 53 systemic corticosteroid 53 baseline LDH 53 metabolic alkalosis 53 undetectable viral 53 diastolic BP 53 depressive symptom 53 T2DM 53 blood Phe levels 53 serum cortisol 53 severe neutropenia 53 log# IU mL 53 transaminases 53 p = NS 53 uM 53 #.#ng/ml 53 g dl 53 Triglyceride levels 53 nondiabetic patients 53 serum magnesium 53 oral allopurinol 53 NPH insulin 53 MADRS 53 composite endpoint 53 nmol L 53 % CI #.#-#.# [003] 53 glycosylated hemoglobin levels 53 detectable HCV RNA 53 Flu Cy 53 mU liter 53 elevated triglyceride levels 53 periprocedural 53 serum prostate 53 elevated IOP 53 mRCC 53 sustained virologic response 53 transaminase levels 53 postdose 53 Tumor shrinkage 53 severe exacerbations 53 CVD mortality 53 plasma viremia 52 nmol liter 52 TTM gross 52 fasting triglycerides 52 affective psychosis 52 Cmax 52 Score TOS 52 FEV1 52 cytogenetic response 52 GERD symptom 52 apo B 52 gadolinium enhancing lesions 52 pooled comparator 52 microbiological eradication 52 mcg kg REBETOL 52 lactate dehydrogenase 52 KRAS mutations occur 52 ‰ ¥ 52 fractional shortening 52 atherogenic dyslipidemia 52 mg kg dose 52 ribavirin therapy 52 hypopneas 52 parkinsonian symptoms 52 aminotransferase ALT 52 umol L 52 ug kg 52 Erythropoietic therapies may 52 serum triglycerides 52 Platelet counts 52 Disease Activity 52 Hazard Ratio 52 XIENCE V demonstrated 52 mL/min/#.# m2 52 #mmHg [001] 52 refractory ischemia 52 IU mL 52 rimonabant #mg 52 serum IGF 52 NYHA functional class 52 serum sodium levels 52 #ng/ml 52 Serum creatinine 52 XIENCE V vs. 52 BCVA 52 Stent thrombosis 52 CD4 + cell 52 DAS# remission 52 nonfasting triglycerides 52 platelet aggregation 52 HBeAg negative patients 52 highly emetogenic 52 virological response 52 experienced virologic failure 52 corrected QT interval 52 Hematologic toxicity 52 tipranavir r 52 mcg kg 52 sulfasalazine 52 microalbuminuria 52 advanced adenoma 52 systolic diastolic blood 52 nondepressed 52 biochemical recurrence 52 neutropenia dehydration dyspnea 52 fasting blood glucose 52 left ventricular diastolic 52 pmol L 52 mg ustekinumab 52 microvascular complications 52 creatinine levels 52 mcg dL 52 pulmonary exacerbations 52 transaminase 52 posttransplant 52 intact parathyroid hormone 52 chlorambucil 52 Fasting blood glucose 52 dapagliflozin plus 52 -#.# ± [002] 52 lopinavir r 52 serum HCV RNA 52 #μg [001] 52 Intraocular pressure 52 vitreous haze 52 Vancocin p = 52 plasma cortisol 52 serum concentrations 52 quetiapine risperidone 52 clinically meaningful reductions 52 μg ml 52 Non inferiority 52 abdominal pain flatulence 52 serum CRP 52 thromboembolic complications 52 macrovascular 52 thyroglobulin 52 prolactin levels 52 CSBMs 52 Solid Tumors criteria 52 plasma uric acid 52 Lantus ® 52 subscore 52 response CCyR 52 locoregional recurrence 52 undetectable HCV RNA 52 IIIa inhibitor 52 CDI recurrence 51 hsCRP levels 51 serum creatinine 51 Hb A1c 51 AST ALT 51 receiving ISENTRESS 51 seropositive patients 51 Unified Parkinson Disease 51 mg XP# 51 periprocedural MI 51 peripheral sensory neuropathy 51 response pCR 51 flutamide 51 IU ml 51 angiographic restenosis 51 cerebral oxygenation 51 fasting glucose levels 51 CR CRu 51 abdominal distention 51 statistically significant p 51 eGFR 51 glycemia 51 foveal thickness 51 MADRS scores 51 preoperatively 51 mCi kg 51 complete cytogenetic 51 nonfatal myocardial infarction 51 iPTH 51 HbA 1C 51 scores TNSS 51 conjunctival hyperemia 51 fluticasone salmeterol 51 hemoglobin Hb 51 timolol 51 chloride secretion 51 CK # plasma concentrations 51 dysuria 51 postprandial glucose 51 infliximab monotherapy 51 partial remissions 51 Ejection Fraction 51 glycosylated hemoglobin 51 estimated glomerular filtration 51 oral vancomycin 51 â ‰ ¥ 51 bezafibrate 51 mIU ml 51 vertebral fracture 51 PNH patients 51 mucosal healing 51 splenectomized patients 51 plus MTX 51 macular thickness 51 #mg/day [001] 51 parasitaemia 51 LS BMD 51 orthostatic hypotension 51 varices 51 SGRQ 51 copies mL 51 elevated uric acid 51 iloprost 51 SSRI SNRI 51 arterial oxygen saturation 51 Fasting plasma glucose 51 Doxil ® 51 3mg/kg 51 lispro 51 XIENCE V PROMUS Stent 51 residual platelet reactivity 51 nonfatal myocardial infarction MI 51 diameter stenosis 51 Visual acuity 51 Secondary endpoints include 51 INCB# [003] 51 nanomolar 51 lactate dehydrogenase LDH 51 renal dysfunction 51 N telopeptide 51 SELENA SLEDAI 51 #mg BID [003] 51 diastolic hypertension 51 hepatorenal syndrome 51 non splenectomized 51 femoral neck BMD 51 aldosterone antagonist 51 steroid dexamethasone 51 IL 1ß 51 sweat chloride 51 confidence interval #.#-#.# 51 achieving PASI 51 ATACAND 51 coronary stenosis 51 postop 51 endometrial thickness 51 Visual Analogue Scale VAS 51 Mean Symptom Complex 51 activated partial thromboplastin 51 per deciliter mg 51 mmol 51 radiographic progression 51 mmHg 51 placebo fluoxetine 51 diopters 51 alanine transaminase 51 #mg dose [002] 51 #mg BID [001] 51 PROCTOCORT ® Suppository Hydrocortisone 51 blood Phe 51 glycated hemoglobin HbA1c 51 overt hepatic encephalopathy HE 51 symptomatic intracranial hemorrhage 51 INVEGA ® 51 recurrent ischemia 51 serum phosphorous 51 Zometa hazard 51 mcg albinterferon alfa 2b 51 oxycodone IR 51 dyspnea 51 cells μL 51 hemoglobin concentrations 51 #mg/day [002] 51 TNF alpha IL 51 macrovascular events 51 placebo dexamethasone 51 serum triglyceride levels 51 ug mL 51 desvenlafaxine succinate 51 plus ribavirin 51 systolic dysfunction 51 generalized edema 51 oxygen desaturation 51 FDG uptake 51 CRP marker 51 hemoglobin concentration 51 Nonresidential structures 50 diabetic gastroparesis 50 leukemia AML 50 gout flares 50 Target Lesion Revascularization TLR 50 diastolic pressure 50 incontinence episodes 50 ml kg 50 fasting insulin 50 saline placebo 50 interrater reliability 50 ULORIC 50 Severity Index PASI 50 NATRECOR ® 50 Spherion Employee Confidence Index 50 undetectable HBV DNA 50 NNRTI resistance 50 attain statistical significance 50 fosamprenavir 50 ischemia driven 50 HbA1c 50 virologic breakthrough 50 cytogenetic responses 50 % CI #.#-#.# [006] 50 urate lowering therapy 50 mg/# h 50 Score DAS 50 FluCAM arm 50 visceral adiposity 50 seroprotection 50 hypercalcemia 50 posttreatment 50 p ≤ 50 nicardipine 50 EDSS 50 stented vessel 50 urinary excretion 50 evaluable subjects 50 serum LDL cholesterol 50 alkaline phosphatase 50 ACR# [002] 50 PEGylated Fab fragment 50 serum testosterone levels 50 thyrotropin levels 50 Operative mortality 50 postoperative complication 50 TMC# r 50 nmol l 50 vasodilatation 50 triacylglycerol concentrations 50 daunorubicin 50 #.#mmol L [002] 50 pT3 50 Dec Eurodollars #.# 50 viral titers 50 MoxDuo TM IR 50 Projections ranged 50 mm Hg diastolic 50 FluCAM 50 advanced adenomas 50 distensibility 50 locoregional disease 50 imipenem 50 metformin monotherapy 50 subclinical hypothyroidism 50 isoprostane 50 severe mitral regurgitation 50 perioperatively 50 postoperative mortality 50 Scale PANSS 50 discontinuations due 50 irbesartan 50 QIDS SR 50 nonresponders 50 Fidaxomicin 50 ejection fractions 50 confidence intervals CIs 50 pg mL 50 perioperative mortality 50 timepoints 50 Apidra ® 50 salmeterol fluticasone 50 tissue oxygenation 50 haemorrhagic strokes 50 ruboxistaurin 50 lipid parameters 50 HBeAg negative 50 Loss severities 50 viral kinetics 50 clinicopathological features 50 AVODART 50 Hypotension 50 octreotide LAR 50 baseline PASI 50 nasal obstruction 50 specific antigen PSA 50 spontaneous bowel movements 50 troponin T 50 Acetate Rectal Suppositories 50 timepoint 50 unfractionated heparin UFH 50 confirmed CCyR 50 calculated creatinine clearance 50 systolic function 50 QD dosing 50 elevated creatinine 50 lipoprotein Lp 50 nM 50 cTnT levels 50 lowest tertile 50 hyperemia 50 virological suppression 50 #Gy 50 bronchial hyperresponsiveness 50 cells mcL 50 g dL 50 subtrochanteric 50 mg qd 50 MS relapses 50 Eur J Endocrinol 50 low dose Iluvien 50 OGTT 50 primary aldosteronism 50 ALVESCO 50 nadolol 50 relapsed MM 50 Lupuzor ™ 50 triglyceride concentration 50 receiving Vectibix monotherapy 50 HIV RNA 50 min -1 50 plus dexamethasone 50 nonsignificant difference 50 dosing frequency 50 piperacillin tazobactam 50 invasive ductal 50 mg dL 50 confidence interval CI 50 acneform rash 50 sensitivity specificity 50 acute bipolar mania 50 mg d 50 MACCE 49 OADs 49 hemoglobin A1C 49 micromoles 49 paraprotein 49 stent binary restenosis 49 diuretic chlorthalidone 49 thyrotropin 49 lymphocyte count 49 hematopoietic cancers 49 psychiatric comorbidity 49 ischemic cardiomyopathy 49 platelet counts 49 RLAI 49 TCE TA 49 NYHA class 49 primary efficacy endpoint 49 dichotomized 49 liver enzymes ALT 49 total cholesterol LDL 49 mg/m2/day 49 cervical intraepithelial neoplasia 49 IRLS 49 segment binary restenosis 49 #OHD 49 adenoma recurrence 49 CLA supplementation 49 deep venous thromboses 49 recurrent glioblastoma multiforme 49 hepatic enzymes 49 carotid stenosis 49 clinically meaningful improvement 49 triiodothyronine 49 NNT = 49 tricuspid regurgitation 49 ventricular tachyarrhythmia 49 mg Proellex 49 median PFS 49 mmol liter 49 renal scarring 49 TNF antagonist 49 mg kg ip 49 amoxicillin clavulanate 49 mol L 49 DAS# scores 49 ≥ 49 dose cytarabine 49 Response Evaluation Criteria 49 #.#mmHg 49 colorectal adenoma 49 CIMZIA TM certolizumab pegol 49 dose cohorts 49 oral antidiabetes 49 metformin sulfonylurea 49 fatigue asthenia 49 hematological parameters 49 virologic failure 49 candesartan cilexetil 49 Severe hypoglycemia 49 aortic insufficiency 49 MELD scores 49 CHD mortality 49 apnea hypopnea 49 immuno suppression 49 plasma concentrations 49 Postoperatively 49 cerebral oxygen saturation 49 titers 49 MIC# [001] 49 intravaginal ejaculatory latency 49 flow mediated dilation 49 PRADAXA #mg 49 interobserver reliability 49 IOP lowering 49 FOLFOX4 49 aminotransferase elevations greater 49 c reactive protein 49 elevated LDH 49 corrected visual acuity 49 triglyceride concentrations 49 FDA defined valvulopathy 49 mU L 49 ALT normalization 49 mIU mL 49 T2 lesion volume 49 Joseph Piotroski benchmark 49 nonfatal stroke 49 coronary calcification 49 upper gastrointestinal bleeding 49 histologic subtype 49 systolic BP 49 μg d 49 angiographic outcomes 49 TAXUS Express Stent 49 -8 -9 49 elevated LDL cholesterol 49 cEVR 49 LEXIVA r 49 abnormal p# biomarker 49 5-FU/LV 49 Breslow thickness 49 μg L 49 nodular partial response 49 CANCIDAS 49 adenoma 49 anastomotic leak 49 budesonide pMDI 49 fasting triglyceride levels 49 FOLPI regimen 49 APTIVUS r 49 hyperkalemia 49 wound dehiscence 49 primary hypercholesterolemia 49 linaclotide treated 49 imatinib therapy 49 #mg QD [002] 49 mitral regurgitation 49 Ischaemic Stroke 49 GSTM1 49 PaO 2 49 nocturnal hypoglycemia 49 arteriolar 49 mm Stent 49 bioavailable testosterone 49 vWF 49 Decitabine 49 #mg/dL [002] 49 thromboembolic events 49 ug ml 49 K ras mutations 49 cardiovascular mortality 49 hydroxyvitamin D levels 49 idraparinux 49 receiving INTRON 49 HGPIN 49 eplerenone 49 alemtuzumab treated 49 fructosamine 49 posaconazole 49 transferrin saturation 49 CNS LS 49 endophthalmitis 49 Suicidal ideation 49 BARACLUDE ® 49 cTnI 49 Taxus Stent 49 hyperuricemia 49 rectal tenesmus 49 serum potassium levels 49 ejection fraction 49 malperfusion 49 dexamethasone Decadron 49 PAOD 49 detrusor 49 hemorrhagic complications 49 angiotensin converting enzyme inhibitors 49 ventricular dysfunction 49 mmHg p = 49 mean baseline A1C 49 onset diabetes mellitus 49 OAB symptoms 49 Retisert TM 49 statistical significance p 49 symptomatic intracranial 49 serum glucose 49 placebo 49 RBP4 levels 49 μg kg 49 intravesical therapy 49 secondary endpoint 49 Febrile neutropenia 49 dose colchicine 49 hemodynamically significant 49 peginterferon alfa 2b 49 serum TSH 49 ritonavir boosted 49 non menstrual pelvic 49 cGy 49 nonoperative treatment 49 prespecified 49 plasma folate 49 pulmonary infiltrates 49 ng mL 49 progesterone receptor negative 49 cisplatin vinorelbine 48 neointimal 48 p# activation 48 CsA 48 Shorted shares 48 hepatotoxicity 48 prednisone prednisolone plus 48 pg ml 48 nausea photophobia 48 rosuvastatin #mg 48 psychosocial functioning 48 pegaptanib 48 IFN alfa 48 mm Hg 48 cerebrovascular events 48 baseline FEV 48 6R BH4 48 neurologic outcomes 48 mild renal insufficiency 48 #mmHg [002] 48 trough FEV1 48 viraemia 48 #mg/dl 48 nonvertebral fractures 48 intraclass correlation coefficient 48 Hazard Ratio HR 48 severe hypoglycemic 48 invasive aspergillosis 48 divalproex sodium 48 euthymic patients 48 somnolence headache 48 #OHD levels 48 reintervention 48 osmolality 48 interferon beta therapy 48 median survivals 48 chlorthalidone 48 mg tid 48 liver metastasis 48 HES CEL 48 antipsychotic efficacy 48 CI #.#-#.# [001] 48 μg doses 48 BMI #-#.# 48 adalimumab 48 plasma glucose 48 carotid intima media 48 aPTT 48 antioxidant supplementation 48 uncontrolled asthma 48 Cream USP 1 48 stable angina pectoris 48 EpCAM expression 48 thrombocytopenia anemia 48 oxyhemoglobin 48 subclinical cardiovascular disease 48 mcg ml 48 systemic corticosteroids